FONAR Corporation

NASDAQ:FONR

Medical - Devices

Healthcare
$19.09 +0.00%

+$0.00 today

Market cap
$117.76M
Beta
0.95
P/E (TTM)
17.6
EPS (TTM)
$1.08
52W Low $13.62High $19.16

Volume 0.00M

Average 0.08M

FONR Interest Income

Income earned on cash, deposits, and investments held by the company.

FONAR CorporationNASDAQ: FONR

Interest Income · Q3 FY2026 · quarter ended Mar 2026

Interest income dips below year-ago levels

Q3 FY2026 interest income of $375K fell 19.0% year over year, behind the +290.9% change in trailing-twelve-month interest income. Sequentially, it fell 15.3% from the prior quarter.

Context

  • Interest income amounted to 2.1% of revenue in FY2025, up 2.1 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -19.0% toward the trailing-twelve-month pace of +290.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$375K-15.3% QoQ
Last fiscal yearJun 2025
$2.17M— YoY
LTMMar 2026
$1.81M+290.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.17M USD
Year-over-year change
—

Interest Income vs competitors

How FONR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +290.9% is the highest of 6, against a peer median of -41.9%.
  • Interest income amounts to 1.7% of revenue for FONR, versus a peer median of 2.4%.
FONR Competitors
Interest Income for FONR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$5.01M USD-23.7%+66.4%—
LUNGPulmonx CorporationLTM Mar 2026$2.14M USD-52.3%+20.1%2.4%
FONRFONAR CorporationLTM Mar 2026$1.81M USD+290.9%—1.7%
IFRXInflaRx N.V.LTM Mar 2026€1.62M EUR-41.9%+42.8%5520.1%
APYXApyx Medical CorporationLTM Mar 2026$1.05M USD-25.9%+91.8%1.9%
HYPRHyperfine, Inc.LTM Mar 2026$960K USD-52.3%+10.4%6.3%
RCELAVITA Medical, Inc.LTM Mar 2026$0 USD——0.0%
VANIVivani Medical, Inc.LTM Mar 2026$0 USD———
Peer median (excluding FONR) —-41.9%+42.8%2.4%

Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue89.93M97.59M98.65M102.88M104.35M
Cost of Revenue46.46M50.58M52.9M57.74M61.44M
Gross Profit43.47M47.01M45.75M45.14M42.91M
Gross Margin48.3%48.2%46.4%43.9%41.1%
Research & Development1.64M1.49M1.57M1.74M1.58M
Selling, General & Admin0029.39M029.73M
Operating Expenses26.38M25.01M30.96M28.6M31.31M
Depreciation & Amortization4.08M4.54M8.8M4.6M4.7M
EBITDA22M27.65M24.61M23.94M18.5M
EBITDA Margin24.5%28.3%25.0%23.3%17.7%
Operating Income17.1M22.01M14.79M16.54M11.6M
Operating Margin19.0%22.6%15.0%16.1%11.1%
Interest Income00002.17M
Interest Expense248.67K346.55K50.13K77K25.61K
Other Income / Expenses567.72K761.69K969.33K2.73M2.18M
Income Before Tax17.67M22.77M15.76M19.27M13.78M
Pre-Tax Margin19.6%23.3%16.0%18.7%13.2%
Income Tax Expense3.99M5.53M3.63M5.17M3.11M
Net Income10.21M12.44M9.38M10.57M8.33M
Net Margin11.4%12.7%9.5%10.3%8.0%
EPS (Basic)1.471.781.351.561.26
EPS (Diluted)1.451.751.321.531.23
Weighted Avg Shares6.61M6.55M6.65M6.35M6.32M
Weighted Avg Shares (Diluted)6.74M6.68M6.77M6.48M6.55M

FONAR Corporation

NASDAQ:FONR

Intrinsic Alpha fair value

Locked

Current Price

$19.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.